Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
Eversense 365 gives you real-time glucose readings through a small sensor that’s placed just under the skin of your upper arm by a healthcare provider. The smart transmitter sits above the sensor, sending glucose data to your app. Want to learn more about the science behind Eversense? Check out our “How Eversense Works” video!
No, clinical study data (PROMISE Study) did not indicate this.
DO NOT use the Eversense® Apps on jailbroken or rooted devices.
Jailbroken devices do not provide an acceptable level of security and accuracy for the user, and are not approved for use by Senseonics
While it is possible, in the Eversense E3 pivotal clinical trial (PROMISE Study), most users were in 1 calibration/day 62% of the time and in 2 calibrations a day 38% of the time, after day 21.
The simple answer is no. While you may optionally calibrate the Eversense E3 System more frequently, (daily calibrations entries must be spaced at least one hour apart), this will not impact the accuracy of the system.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1